Related Experiment Video
Updated: May 6, 2026
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
[Medical treatment of renal cell carcinoma]
1Faculté de médecine, université d'Auvergne, 28, place Henri-Dunant, BP 38, 63001 Clermont-Ferrand cedex 1, France; Service d'urologie, hôpital G.-Montpied, 58, rue Montalembert, 63003 Clermont-Ferrand cedex 1, France.
Aim:
To describe drugs used in renal cell carcinoma.
Method:
Pubmed search for efficacy, mode of action and side effects for each molecule. Additional data were searched from the French regulatory agencies websites (HAS and ANSM).
Results:
Since 2007, a total of three different therapeutic classes in the management of metastatic renal cell carcinoma are available. These three classes are tyrosine kinase inhibitors with sunitinib and sorafenib, the anti-VEGF antibodies (bevacizumab which is associated with alpha interferon in the treatment of advanced kidney cancer) and mTOR inhibitors with temsirolimus and everolimus. These targeted therapies are a major progress in the treatment of patients with metastatic kidney cancer. The side effects encountered with these molecules are numerous but serious side effects are less than 5% of all reported side effects.
Conclusions:
A better understanding of molecular mechanisms has enabled the development of new therapies for the treatment of metastatic renal cell carcinoma. In the future, a personalized approach taking into account the biology of each tumor could be created to provide a more targeted treatment.
Insights
New targeted therapies, including tyrosine kinase inhibitors, anti-VEGF antibodies, and mTOR inhibitors, have advanced metastatic renal cell carcinoma treatment. While side effects occur, serious adverse events are infrequent, improving patient outcomes.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Metastatic renal cell carcinoma (mRCC) treatment has evolved significantly.
- Understanding molecular pathways has driven therapeutic innovation.
Purpose of the Study:
- To review current drug therapies for renal cell carcinoma.
- To describe the efficacy, mechanism of action, and side effects of mRCC drugs.
Main Methods:
- Literature search of PubMed for relevant studies.
- Review of efficacy, mode of action, and side effects of targeted therapies.
- Data collection from French regulatory agency websites (HAS, ANSM).
Main Results:
- Three main classes of targeted therapies are available for mRCC since 2007: tyrosine kinase inhibitors (sunitinib, sorafenib), anti-VEGF antibodies (bevacizumab with interferon-alfa), and mTOR inhibitors (temsirolimus, everolimus).
- These targeted therapies represent significant progress in managing advanced kidney cancer.
- Reported side effects are numerous, but serious adverse events occur in less than 5% of cases.
Conclusions:
- Advances in understanding molecular mechanisms have led to novel mRCC therapies.
- Future treatment may involve personalized approaches based on tumor biology for more targeted interventions.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
07:50Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts
Published on: May 25, 2018
Related Concept Videos
01:30Urinary Tract Calculi III: Medical Management
01:26Kidney Transplant II: Surgical Procedure
01:28Chronic Kidney Disease III: Interprofessional Care
01:25Urinary Tract Calculi VI: Surgical Management
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
02:56Treatment Resistent Cancers